FUNCTION OF GUT PEPTIDES IN ISOLATED GUT MUSCLE CELLS
Project Number2R01DK028300-14
Contact PI/Project LeaderMAKHLOUF, GABRIEL M.
Awardee OrganizationVIRGINIA COMMONWEALTH UNIVERSITY
Description
Abstract Text
The objective of this proposal is to characterize the receptors,
signalling pathways and cellular mechanisms involved in relaxation of
gastric smooth muscle by transmitters of the myenteric plexus. The focus
is on peptide receptors coupled to multiple interactive pathways that
mediate or modulate relaxation. The experimental approach exploits a
technique for selective, site-directed receptor protection that allows
each pathway to be examined separately and is based on the discovery of
an important link between the myenteric neuropeptide, VIP release; in
turn, VIP stimulates (i.e., re-generates) NO in target muscle cells. The
link to VIP confers receptor specificity on NO signalling and engages
both limbs of the cyclic nucleotide system that sustains relaxation.
Accordingly, the Specific Aims of the proposal are: (1) to characterize
receptors for NPY, opioid peptides, acetylcholine and 5-HT, which are
coupled to IP, generation and IP-dependent Ca release via one receptor
subtype, and to increase (5-HT and muscarinic M) or decrease (NPY Y,
opioid mu, delta, kappa, and muscarinic M) in cAMP via a distinct
receptor subtype; (2) to characterize receptors for VIP and the myenteric
homologous peptide, PACAP, in isolated gastric muscle cells which are
coupled to stimulation of adenylate cyclase and NO-dependent stimulation
of guanylate cyclase; our continuing studies in plasma membranes derived
from isolated muscle cells have demonstrated the presence of a membrane-
bound, constitutive, G protein-coupled, Ca2+/calmodulin-sensitive NO
synthase which is specifically activated by VIP and PACAP; and (3) to
identify the loci of regulatory phosphorylation by cAMP- and cGMP-
dependent protein kinase (cA-kinase and cG-kinase) which mediate
relaxation. In comparative studies using cA-kinase and cG-kinase
inhibitors including PKI (6-22) amide, a highly specific inhibitor of
cA-kinase, we have identified concentrations of inhibitors that
selectively block cA-kinase activity (H-89, Rp-cAMPS) and cG-kinase
activity (the indole carbazole KT5823). This development set the stage
for identification of events in the signalling cascade that, based on
preliminary results, are preferentially regulated by cA-kinase (IP3
generation, IP3-dependent Ca2+ release) and cG-kinase (sarcoplasmic Ca
uptake) or equally regulated by both kinases (Ca/calmodulin sensitivity
of MLC kinase and MLC phosphorylation). The combined approach embodied
the three aims should advance our understanding of the cellular
mechanisms mediating smooth muscle relaxation.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
DUNS Number
105300446
UEI
MLQFL4JSSAA9
Project Start Date
01-April-1984
Project End Date
31-March-1999
Budget Start Date
01-April-1994
Budget End Date
31-March-1995
Project Funding Information for 1994
Total Funding
$149,372
Direct Costs
$103,015
Indirect Costs
$46,357
Year
Funding IC
FY Total Cost by IC
1994
National Institute of Diabetes and Digestive and Kidney Diseases
$149,372
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 2R01DK028300-14
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 2R01DK028300-14
Patents
No Patents information available for 2R01DK028300-14
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 2R01DK028300-14
Clinical Studies
No Clinical Studies information available for 2R01DK028300-14
News and More
Related News Releases
No news release information available for 2R01DK028300-14
History
No Historical information available for 2R01DK028300-14
Similar Projects
No Similar Projects information available for 2R01DK028300-14